Cantor Fitzgerald Reiterates Overweight Rating on Fulcrum Therapeutics (FULC)

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $10.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).

The analyst commented, "FULC has been a high inbound name that has come up a lot on marketing trips, and a readout that we think the Street is paying close attention to. Generally speaking, many are believers in the mechanism and the potential efficacy profile of inducing fetal hemoglobin (and the nice data that show how increasing rates could reduce vaso-occlusive crises, VOCs). Big questions remaining around the name are 1) what the risk/ benefit profile has to be for doctors to use pociredir and 2) how the FDA will read the data to potentially expand the eligible population. Based on where the stock is trading, we believe there is more value to unlock in the stock, even with the most conservative patient population alone. Should the data exceed expectations, this could potentially open the door to broader market potential, with even more upside to our estimates."

For an analyst ratings summary and ratings history on Fulcrum Therapeutics click here. For more ratings news on Fulcrum Therapeutics click here.

Shares of Fulcrum Therapeutics closed at $6.36 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Paramount Skydance clears global regulators for WBD deal, faces state AG suit